Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues up a third in 2023, sparking a rise in an already inflated share price that briefly pushed the group’s valuation above $500 billion this morning.
Copyright © 2024 | WordPress Theme by MH Themes
